Key Highlights
- UNH stock began trading at $277.32, significantly below its 52-week peak of $606.36
- Several analysts reduced price targets — JPMorgan to $389, Truist to $370, UBS to $410
- Weiss Ratings issued a Sell rating for UNH in early March
- Q4 earnings per share of $2.11 slightly exceeded forecasts; revenue increased 12.3% to $113.73 billion
- Wall Street consensus shows Moderate Buy with an average target of $372.13
UnitedHealth Group (UNH) has encountered significant challenges recently. Shares opened at $277.32 on Monday, trading considerably below the 50-day moving average of $297.19 and the 200-day moving average of $324.39.
This represents a substantial decline from the 52-week peak of $606.36. The stock’s 52-week low stands at $234.60.
The healthcare giant currently maintains a market capitalization of $251.71 billion, carrying a price-to-earnings ratio of 21.02 and a beta of 0.41.
The company’s debt-to-equity ratio registers at 0.72, while both current and quick ratios are positioned at 0.79.
During January, UnitedHealth disclosed Q4 earnings of $2.11 per share, marginally surpassing the consensus forecast of $2.09. Revenue totaled $113.73 billion, reflecting a 12.3% year-over-year increase and edging past analyst projections.
However, the Q4 EPS figure represents a substantial decline compared to the $6.81 reported during the corresponding quarter of the previous year.
Wall Street Reduces Price Forecasts
Numerous prominent financial institutions have reduced their price forecasts in recent weeks.
JPMorgan lowered its target from $425 to $389, Morgan Stanley adjusted downward from $411 to $409, and UBS decreased from $430 to $410. Truist implemented the most aggressive reduction, dropping from $410 to $370. Despite these cuts, all four firms retained Buy or Overweight recommendations.
Weiss Ratings took a more decisive stance, downgrading UNH from Hold to Sell during early March.
MarketBeat’s current consensus indicates a Moderate Buy rating, featuring 17 Buy ratings, 8 Holds, and 2 Sells. The average 12-month price forecast stands at $372.13 — suggesting approximately 34% potential upside from present levels.
Regarding institutional activity, significant movements have occurred. Wealth Enhancement Advisory Services reduced its position by 40.6% during Q4, divesting 170,643 shares. Conversely, Norges Bank, Berkshire Hathaway, and Capital Research Global Investors either expanded or established positions throughout 2024. Institutional investors collectively control 87.86% of outstanding shares.
Ongoing Regulatory Challenges
Department of Justice examination regarding Medicare Advantage reimbursement practices continues to impact investor sentiment. While the company has achieved at least one positive legal outcome in the matter, widespread regulatory pressure concerning prior-authorization procedures and coverage denial practices persists.
Executives have previously disclosed intentions to reduce certain Medicare Advantage enrollees and adjust product pricing in response to the changing cost landscape.
The company issued FY2026 EPS guidance of approximately $17.75. Analysts currently project full-year EPS of $29.54 for the ongoing fiscal year.
UNH distributed a quarterly dividend of $2.21 per share on March 17, translating to an annualized yield of approximately 3.2%. The current payout ratio sits at 67.02%.
On a more optimistic note, UnitedHealth recently revealed a nationwide expansion of its doula benefit program, which may enhance member retention and strengthen outcomes within its value-based care framework.
